Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Internal Medicine (IM platinum) > Ischemic Heart Disease > Flashcards

Ischemic Heart Disease Flashcards

1
Q

2 groups of Ischemic Heart Disease

A
  • Stable coronary artery disease (SCAD)
    • Stable chronic angina pectoris (CSAP)
  • Acute coronary syndrome (ACS), which are composed of:
    • Non-ST segment elevation acute coronary syndrome (NSTE-ACS), which includes:
      • Unstable angina(UA)
      • Non-ST-segment elevation myocardial infarction (NSTEMI)
    • ST-segment elevation acute myocardial infarction (STEMI)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Etiopathogenesis of Stable Coronary artery Disease

A
  • Inadequate supply of blood flow and oxygen to a portion of the myocardium causing inadequate perfusion of myocardium (ischemia) supplied by an involved coronary artery
  • Usually inducible by :
    • Stress
    • exercise
    • emotion
  • Most common cause:
    • Atherosclerotic disease of an epicardial coronary artery
  • Obesity, insulin resitance, and T2DM are increasing and powerful risk factors for IHD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Clinical Manifestation of Chronic Stable Angina Pectoris (CSAP)

A
  • Typical history involves a man >50 years old or woman >60 years old who complains of Chest discomfort:
    • Described as heaviness, pressure, squeezing, smothering, or choking
    • Crescendo-decrescendo in nature
    • Usually lasts 2-5 minutes
    • Associated with physical exertion on stress
    • Radiation to either or both shoulders/arms, but does not radiate to the trapezius muscles
    • Releived within 5-10 mins by rest and/or sublingual nitroglycerin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hand placed over sternum with a clenched fist to indicate a squeezing, central, substernal discomfort

A

Levine’s sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Canadian Cardiovascular Society Classification of Angina

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Typical vs Atypical Angina

A
  • Substernal chest discomfort of characteristic quality and duration
  • Provoked by exertion or emotional stress
  • Releived by rest and/or nitrates within minutes

TYPICAL ANGINA : all 3

ATYPICAL ANGINA: Meets only 2 of the 3

NON-ANGINAL PAIN: Meets only one or none of the manifestions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Basic Laboratory Work-up for SCAD

A
  • CBC: Anemia may trigger ischemia
  • Fasting lipid profile and FBS/HbA1c: to identify risk factor such as dyslipidemia and diabetes
  • Baseline liver and kidney function prior to starting medications
  • Others:
    • Consider thyroid function tests, BNP/NT-proBNP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

12-Lead Electrocardioogram for SCAD

A
  • May be normal at rest - but it does not exclude diagnosis of ischemia (stress testing may be needed)
  • May find ST-segment and T-wave changes, LV hypertrophy, Intraventricular conduction disturbances, arrythmias
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chest Radiograph for SCAD

A
  • Does not provide specific information for SCAD
  • May be useful to rule out other non-cardiac causes of chest pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

2D echo for SCAD

A
  • used to assess left ventricular function in patients with CSAP and patients with a history of a prior MI, pathologic Q waves, or clinical evidence of CHF
  • Assess for wall motion abnormalities, ejection fraction, presence of thrombus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Stress testing for SCAD

A
  • ECG exercise testing: most widely used for both diagnosis of IHD and estimating prognosis; involves recording the 12-Lead ECG before, during and after exercise
  • Stress imaging (stress echpcardiography, radionuclide perfusion or MPI, stress cardiac MRI) : preferred when the resting ECG is already abnormal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

CT Angiography (CTA) and calcium score

A
  • CTA: imaging technique for anatomical diagnosis of obstructive coronary lesionsl used as an alternative to stress imaging to”rule out” SCAD, since it is a high sensitivity test
  • Calcium score: calcified lesions are quantified using the Agatston score
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indications for Coronary Angiography

A
  • Patients with CSAP who have survived cardiac arrest or life-threatening ventricular arrhythmia
  • Patients with CSAP with severe symptoms despite optimal medical therapy
  • Patients with high cardiac event risk (e.g., death, AMI) based on noninvasive testing, regardless of symptoms
  • Patients with troublesome symptoms that present diagmostic difficulties in whome there is a need to confirm or rule out the diagnosis of IHD
  • Patients with CSAP or evidence of ischemia on noninvasive on noninvasive testing with clinical or laboratory evidence of ventricular dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Control of Risk factors and Lifestyle medication for SCAD

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

3 drugs focus primarily on reducing acute thrombotic events and LV dysfunction in patients with SCAD

A
  • Aspirin
  • ACE-inhibitors
  • Statins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drugs that is shown to reduce mortality in SCAD with LV dysfunction following Myocardial infarction

A
  • Beta Blockers
  • ACE-inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DRUGS USED IN SCAD (prevention of mortality and morbidity)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Pharmacologic Treatment for relief of angina (ANTI-ISCHEMIC DRUG)

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Other Anti-Ischemic Drugs for SCAD

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Percutaneous Coronary Intervention (PCI)

A
  • Balloon dilatation usually accompanied by coronary stenting
  • Most common indication is persistent or symptom-limiting angina pectoris, despite medical therapy, accompanied by evidence of ischemia during a Stress test
  • Patients who have received a drug eluting stent will need:
    • Dual antiplatelets for 1 year (Aspirin +ADP-P2Y12-Inhibitor), then
    • SIngle antiplatelet indefinitely (usually aspirin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cronary Artery Bypass Grafting

A
  • Done to Achieve complete revascularization by grafting all coronary arteries of sufficient caliber that have significant proximal stenoses
  • Preferred approach for:
    • Left main CAD
    • 3 vessel CAD, especially if with LV dysfunction
    • 2 vessel CAD with significant proximal left anterior descending artery disease with LV dysfunction or high risk findings on non-invasive tests
    • Patients with multi-vessel CAD and Diabetes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Operational term that refers to a pectrum of conditions compatible with acute myocardial ischemia and/or infarction due to an abrupt reduction in coronary blood flow

A

Acute Coronary Syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hallmark of Acute Coronary Syndrome (ACS)

A

Sudden imbalance between myocardial oxygen consumption (MVO2) and demand usually due to coronary obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Patients with ACS are composed of..

A
  • Non-ST segment elevation ACS (NSTE-ACS) divided according to presence of necrosis biomarker:
    • Non-ST segment elevation myocardial infarction (NSTEMI)
    • Unstable angina (UA)
  • ST-segment elevation myocardial infarction (STEMI)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Criteria for Acute Myocardial Infarction
* "Acute MI" should be used when there is evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia Under these conditions any of the following criteria meet the diagnosis of MI: * **Detection of a rise and/or fall in cardiac biomarkers** (preferably cardiac troponins/cTn), with at least one value above the 99th percentile with at least one of the following: * Symptoms of Ischemia * New or presumed new significant ST-segment and/or T wave changes or new LBBB * Development of pathologic Q waves on the ECG * Imaging evidence of a new loss of viable myocardium or new wall motion abnormality * identification of an intracoronary thrombus by angiography or autopsy * **Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new LBBB (Type 3)** * **PCI-related MI (type 4a)** * **Stent thrombosis associated with MI (type 4b)** * **CABG-related MI (type 5)**
26
Criteria for Previous Myocardial Infarction
Any of the following: * **Pathologic Q waves** with or without symptoms in the absence of non-ischemic causes * Imaging evidence of a r**egion of loss of viable myocardium** that is thinnd and fails to contract in the absence of a non-ischemic * **Pathologic finding of previous MI**
27
Universal Classification of Types ofMyocardial Infarction
28
**Type of MI** Related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries that leads to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis
TYPE 1 | (Spontaneous MI)
29
**Type of MI** A condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand (e.g., coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachyarrhythmias/bradyarrhythmias, anemia, respiratory failure, hypotension, and hypertension with/without LV hypertrophy
Type 2 MI secondary to Ischemic Imbalance
30
**Type of MI** Cardia death with symptoms suggestive of ischemia and presumed new ischemic changes (or new LBBB), but death occuring before blood samples could be ontained
Type 3 MI resulting in Death when biomarkers are Unavailbale
31
**Type of MI** Defined by elevation of cardiac troponin values \>5x the 99th percentile of the upper reference limit in those with normal baseline values or a rise in cTn values \>20% if baseline values are elevated and are stable or falling: and one of the following * Symptoms suggestive of MI * new Ischemic changes on the ECG or new LBBB * Angiographic loss of patency of a major coronary artery or a side branch or persistent slow flow or no flow or embolizaion * Imaging demonstration of a new loss of viable myocardium or new regional wall motion abnormality
Type 4a MI related to PCI
32
**Type of MI** Associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial schemia and with a rise and/or fall in cardiac biomarkers with at least one value \>99th percentile of the upper reference limit
Type 4b MI related to stent thrombosis
33
Type of MI Defined as elevation of cardiac biomarker values \>10x the 99th percentile of upper refernce limit in patients with normal bseline values; AND either; * New pathologic Q waves or new LBBB or * new graft or new native coronary artery occlusion on angiogram or * Imaing evidence of new loss of viable myocardium or new regional wall motion abnormality
Type 5 MI related to CABG
34
Myocardial infarction with Non-Obstructive Coronary Arteries **(MINOCA)**
* AMI occuring in the absence of obstrucibe (\>50%) CAD
35
Etiologies of MINOCA
1. Secondary to coronary artery disease (MI type 1) 2. Imbalance between oxygen supply and demand (MI type 2) 3. Coronary endothelial dysfunction (MI type 2) 4. Secondary to myocardial disorders without involvement of coronaries
36
Etiopathogenesis of NSTE-ACS
* Most commonly caused by imbalance between oxygen supply and demand * usually due to a partially occluding thrombus forming on a disrupted coronary plaque or on eroded coronary artery endothelium
37
Four Basic Pathophysiologic processes for NSTE-ACS
* Most common cause: * Plaque rupture or erosion with superimposed non-occlusive thrombus * Dynamic obstruction (e.g., coronary spasm as in Prinzmetal's variant angina) * Severe mechanical obstruction (e.g., stent thrombosis) * Increased myocardial O2 demand (e.g., tachycardia) and/or decreased supply (e.g., anemia)
38
Angina or equivalent ischemis discomfort with at least one of the following: * occurs at rest (or with minimal exertion), usually lasting \>10 minutes * Severe and of new onset (i.e., within the prior 4-6 weeks) of at least CCS III severity * Occurs with a crescendo pattern (i.e., distinctly more severe, prolonged, or frequent than previous episodes)
Unstable Angina
39
Clinical features of UA plus evidence of myocardial necrosis (elevated cardiac biomarkers)
NON-ST-segment Elevation Myocardial Infarction (NSTEMI)
40
Ischemic pain that occurs at rest but not usually with exertion, associated with transient ST-segment elevation Due to transient, focal spasm of an epicardial coronary artery
Prinzmetal Variant Angina
41
Symptoms of NSTE-ACS
* Symptoms that **Increase** **likelihood** of AMI * Typical pain with radiation to shoulders * Typical pain associated with exertion, diaphoresis, nausea, or vomiting * Symptoms that **Decrease** **likelihood** of AMI * Inframammary location of pain * Pain reproducible with palpation * Pain described as sharp, positional, or pleuritic
42
usual PE findings of NSTE-ACS
* Pale coll skin * tachycardia * S3 or S4 * basilar rales * hypotension
43
12 lead Electrocardiogram of NSTE-ACS
* Should be performed and interpreted within 10 minutes of patient's arrival * Changes may include: * **ST-segment depression** * **new T-wave inversion** * **Transient ST-segment elevation** * May also be initially normal,which is why serial ECGs should be done to detect ischemic changes if patient remains symptomatic with a high suspicion for ACS
44
Cardiac biomarkers for NSTE-ACS
* Elevated levels distinuis patients with NSTEMI from UA * Serial cardiac troponin I or T levels should be obtained to identify a rising and/or falling pattern of values: * First level taken at prescription * Second level taken at 3-6 hours after symptom onset * Additional level taken beyond 6 hours in those with nomal levels ons erial examination when ECG and/or presentation confer an intermediate or high index of suspicion for ACS * Cut off of tropinin value for myocardial necrosis: **99th percentile of the upper reference level**
45
Cardiac troponins vs CK-MB
46
Imaging for NSTE-ACS
47
RISK STRATIFICATION: **TIMI SCORE for NSTE-ACS**
48
Non pharmacologic management of NSTE-ACS
* Bed rest with continuous ECG monitoring * Supplemental oxygen if O2 saturation \<94% * Stool softeners as needed
49
Anti-Ischemic Therapy for NSTE-ACS
50
Standard Medications for NSTE-ACS
* **ACE inhibitors** * Reduce mortality in those with recent MI (especially if EF \<40%) * **ARBs** * Recommended in HF or MI with LVEF \<40% who are ACE-I intolerant * **Aldosterone Blockers** * Recommended in post-MI patients without significant renal dysfunction (whoa re already on ACEi and BB) * **Statins** * High intensity statin therapy should be initiated or continues * Early administration of statins (e.g., atorvastatin 80 mg/day) has been shown to reduce adverse outcomes
51
Antiplatelet Therapy for NSTE-ACS
* **Aspirin** * Established first-line therapy for NSTE-ACS * Platelet cyclooxygenase inhibitor which blocks the synthesis and release of thromboxane A2 (platelet activator), causing decreased platelet aggregation and thrombus formation * **165-325 mg LD chewed (non enteric), then 80-162 mg OD maintenance dose indefinitely** * Contraindications: active bleeding or aspirin intolerance * **P2Y12- inhibitors** * in the absence of high bleeding risk, patients with NSTE-ACS should also receive a P2Y12 inhibitor for up to 1 months (at least 12 months if patient is to undergo PCI with stenting)
52
P2Y12-Inhibitors
53
Anticoagulation Therapy for NSTE-ACS
* Unfractionated Heparin (UFH) * Enoxaparin * Fondaparinux * Bivalirudin
54
Unfractionated Heparin
* **Dose** * **60 U/kg IV bolus** (maximum 4000 U), then **12 U/kg infusion** (1000 U/hour) for **48 hours** or until PCI is performed (most trials continued therapy for 2-5 days) * **Description** * **Mainstay of therapy** * Prevents coagulation by blocking thrombin (factor IIa) and factor Xa * **Daily monitoring of aPTT** is needed to target 50-70 secs or 1.5-2.5 times control
55
Enoxaparin
* **Dose** * **30 mg IV loading dose**, then **1 mg/kg SC q12** for the duration of hospitalization or until PCI is performed * For \>=75 years olf: no IV bolus needed * **Renal adjustment needed** (1 mg/kg SC OD for CrCl \<30) * **Desription** * ​**Superior to UFH** in reducing recurrent cardiac events, especially in patients managed conservatively * **Greater anti-factor Xa** activity (relative to **factor IIa**) inhibits thrombin generation more effectively * **No monitoring needed** (unlike UFH)
56
Fondaparinux
* **DOSE** * **2.5 mg SC OD** for duration of hospitalization or until PCI is performed * **DESCRIPTION** * ​Indirect **factor Xa inhibitor** * Equivalent in efficacy to enoxaparin, but with **lower risk of major bleeding** * Should **not be used as sole anticoagulant** to support PCI, due to **increased risk of catheter thrombosis**
57
Bivalirudin
* **DOSE** * 0.75 mg/kg IV bolus, then infusion of 1.75 mg/kg/hr * **DESCRIPTION** * * Direct thrombin inhibitor
58
Conservative versus Early Invasisve Strategy
59
* Syndrome of severe ischemic pain that usually occurs a rest and it associated with transient ST-segment elevation * Caused by focal spasm of an epicardial coronary artery (most common the RCA)
Prinzmetal's variant Angina
60
Diagnostic hallmark of Prinzmetal's Variant Angina
* Coronary arteriograpy demonstrates transient coronary spasm
61
Main therapeutic agent for Prinzmetal's variant angina
* Nitrates * CCB !!!!Aspirin may increase severity of ischemic episodes
62
Etiopathogenesis of ST-Segment Elevation Myocardial Infarction (STEMI)
* acute plaque rupture is central to the pathogenesis of STEMI * STEMI occurs when coronary blood flow decreases abruptly after a thrombotic (usually total) occlusion of a coronary artery previously affected by atherosclerosis
63
Temporal Stages of STEMI
* Acute: \<7 days * Healing: 7-28 days * Healed: \>=29 days
64
KIllip Scoring for Prognostication for STEMI
65
12-lead EG for **STEMI**
* Must be interpreted within 10 minutes of patient arrival * Total occlusion of an epicardial coronary produces ST-segment elevation, and most ultimately evelove into Q-waves * Diagnosis of STEMI requires: * typcal ST segment elevation in at least 2 contigous leads or new-onset LBBB
66
Cardiac biomarkers and Other Blood tests for **STEMI**
* troponin T and Troponin I: increases after STEMI many times higher than upper reference limit * CK(non specific): rises within 4-8 hours and returns to normal by 48-72 hours * Other blood tests similar to NSTE-ACS
67
Cardiac Imaging for **STEMI**
* Echocardiography: abnormalities of wall motion are almost universally present * Radionuclide techniques such as MPI with **thallium or setamibi** * Cardiac MRI
68
TIMI Risk Score for STEMI
69
Goals of Management for STEMI
* Control of Chest pain * Identify candidates for urgent reperfusion (PCI or thrombolysis) * Hospital phase management and risk stratisfication
70
Initial management in the emergency room for STEMI
71
Control of Chest Pain
72
Supportive care for STEMI
73
Secondary Prevention and Long term Management for STEMI
74
Reperfusion therapy for STEMI
* Reperfusion terapy (fibrinolysis or percutaneous coronary intervention) should be administered to all eligible patients with STEMI with symptom onset within the last 12 hours * Reperfusion is reasonable if symptom onset is between 12-24 hours + evidence of ongoing ischemia (primary PCI preferred in these patients)
75
Time to ECG
* **AHA/ACC 2013** * FMC to ECG : **\<=10 minutes** * **ESC 2017** * FMC to ECG: **\<= 10 minutes**
76
Time to thrombolysis
* **AHA/ACC 2013** * Door to needle time : **\<= 30 minutes** * **ESC 2017** * Time from STEMI diagnosis to start of fibrinolysis: **\<=10 minutes**
77
Time to PCI
* **AHA/ACC 2013** * door to balloon time **\<= 90 minutes** * **ESC 2017** * Time from STEMI diagnosis tp wore crossing **\<= 60 minutes**
78
Primary PCI is preferred in the following
* Time to treatment delays are short: **symptoms \<12 hours** and **PCI can be performed \<120 minutes** from STEMI diagnosis * Contraindication to fibrinolysis, irrespective of time delay from FMC * High risk from STEMI (cardiogenic shock, Killip \>III) * Late presentation of patient (symptom onset \>3 hours) * Diagnosis of STEMI is in doubt
79
Fibrinolysis is preferred in the following
* Symptoms \<12 hours and primary PCI cannot be performed within 120 mins from STEMI diagnosis * Prolonged transport to PCI-capable center with FMC to device time\>120 mins (if initially received in non PCI capable center) * PCI is not available
80
Primary PCI
* Emergent PCI with balloon,s tent, or other device, performed on the infarct-related artery without previous fibrinolytic treatment * For symptoms \<=12 hours: PCI is recommended (over fibrinolysis) when it can bbe performed in a timely fasgion * For symptoms \>12 hours: PCI is recommended in the presence of ongoing ischemia, hemodynamic instability, or life threatening arrhythmias
81
Pharmocoinvasive Strategy
* Fibrolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI strategy (in case of successful fibrinolysis)
82
Rescue PCI
* Emergent PCI performed immediately for failed fibrinolysis **(persistent chest pain and \<50% ST-segment resolution at 60-90 mins after)**
83
Routine Early PCI Strategy after fibrinolysis
Angiography with PCI of infarct-related artery, performed between 2-24 hours after successful fibrinolysis
84
Adjunctive Pharmacotherapyduring Primary PCI
85
Fibrinolysis
* Largest benefit: when offered \< 2hours after symptom onset * Reperfusion strategy when PCI cannot be done in a timely manner * MEchanismof thrombolytics: Promote conversion of plasminogen to plasmin, which then lyses fibrin thrombi
86
Drugs for Fibrinolysis
87
Absolute Contraindications for Fibrinolysis
* Any prior intracranial hemorrhage * Structral cerebral vascular lesion * Malignant intracranial neoplasm * Ischemic Stroke within 3 months (exept acute ischemic stroke within 4.5 hours) * Suspected aortic dissection * Active bleeding or bleeding diathesis * Closed-head or facial trauma within 3 months * Intracranial or infaspinal surgery within 2 months * Severe uncontrolled hypertension (unresponsive to emergency therapy) * For streptokinase, previous treatmeent within the last 6 months
88
Relative Contraindications
* History of chronic, severe, poorly controlled HPN * Significant hypertension at initial evaluation (SBP \>180 mmHg or DBP \>110 mmHg) * History of previous ischemic stroke \> 3months * Dementia * Intracranial pathology not covered in Absolute Contraindications * Traumatic or prolonged (\> 10 minutes) cardiopulmonary resucitation * Major surgery \<3 weeks * Recent (within 2 to 4 weeks) internal bleeding * Noncompressibe vascular punctures * Pregnancy * Active peptic ulcer * Oral anticoagulant therapy
89
Usual Complication of STEMI

Internal Medicine (IM platinum) (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions